Published in Antimicrob Agents Chemother on May 23, 2016
My Cousin, My Enemy: quasispecies suppression of drug resistance. Curr Opin Virol (2016) 0.76
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment. J Virol (2017) 0.75
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir. PLoS One (2016) 0.75
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology (2014) 3.14
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem (2010) 2.87
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 2.82
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother (2008) 2.22
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. Gastroenterology (2015) 1.91
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis (2015) 1.78
Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis (2000) 1.75
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother (2012) 1.56
Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology (2015) 1.47
Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res (2014) 1.36
New insights into the HCV quasispecies and compartmentalization. Semin Liver Dis (2011) 1.18
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis (2014) 1.16
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology (2014) 1.09
Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology (2015) 1.08
A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis (2013) 1.07
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. Clin Ther (2015) 1.02
Treatment of HCV infection with the novel NS3/4A protease inhibitors. Curr Opin Pharmacol (2014) 0.90
Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol (2014) 0.90
Successes and Challenges on the Road to Cure Hepatitis C. PLoS Pathog (2015) 0.90
Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol (2013) 0.88
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat (2015) 0.87
Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. J Virol (2015) 0.85
Influence of mutagenesis and viral load on the sustained low-level replication of an RNA virus. J Mol Biol (2011) 0.85
Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology (2015) 0.84
Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold. Curr Top Microbiol Immunol (2016) 0.83
Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother (2014) 0.82
Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol (2014) 0.82
A framework for inferring fitness landscapes of patient-derived viruses using quasispecies theory. Genetics (2014) 0.81
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses (2015) 0.81
Estimating Fitness of Viral Quasispecies from Next-Generation Sequencing Data. Curr Top Microbiol Immunol (2016) 0.80
Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α18. Sci Rep (2016) 0.78
Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance. Curr Opin Virol (2014) 0.78